Value202020212022202320242025TTMSelling/general/admin expenses14.2 B14.89 B14.25 B12.52 B12.57 B13.25 B—Research & development8.98 B9.54 B10 B11.37 B10.02 B11.2 B—Operating income10.15 B11.69 B9.2 B9.77 B14.54 B17.64 B—Non-Operating Income, Total———————Interest expense, net of interest capitalized———————Non-Operating Income, excl. Interest Expenses———————Unusual income/expense———————Pretax income9.88 B26.14 B8.37 B9.12 B13.64 B16.35 B—Equity in earnings———————Taxes1.81 B2.12 B1.42 B551 M1.7 B2.38 B—Non-controlling/minority interest1 M3 M04 M2 M17 M—After tax other income/expense———————Net income before discontinued operations3.48 B19.43 B6.96 B8.57 B5.66 B7.68 B—Discontinued operations4.59 B4.59 B—6.28 B6.28 B6.28 B—Net income8.07 B24.02 B6.96 B14.85 B11.94 B13.97 B—Dilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders———————Basic earnings per share (Basic EPS)———————Diluted earnings per share (Diluted EPS)———————Average basic shares outstanding———————Diluted shares outstanding———————EBITDA———————EBIT———————Cost of revenue15.12 B15.87 B15.49 B12.47 B12.83 B13.7 B—Other cost of goods sold———————Depreciation & amortization (cash flow)———————
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.